X0306 4 2022-11-10 0 0001516551 Skye Bioscience, Inc. SKYE 0001728413 Emerald Health Sciences Inc. OFFICE 8262 THE LANDING, 200-375 WATER ST. VANCOUVER A1 V6B 0M9 BRITISH COLUMBIA, CANADA 0 0 1 0 Common Stock 2023-02-22 4 A 0 16641486 0.017 A 128028737 D Common Stock 2023-02-22 4 A 0 41379164 0.0386 A 169407901 D Warrants 0.151 2022-11-10 4 J 1 9141486 0 A 2023-11-10 2024-12-30 Common Stock 9141486 9141486 D Warrants 0.017 2023-02-22 4 D 0 9141486 0 D 2023-11-10 2024-12-30 Common Stock 9141486 0 D Warrants with Credit Facility of Oct 5, 2018 0.0386 2023-02-22 4 P 0 2500000 0 D 2018-11-01 2023-11-01 Common Stock 2500000 0 D Warrants with Credit Facility of Oct 5, 2018 - T2 0.0386 2023-02-22 4 D 0 2500000 0 D 2019-02-01 2024-02-01 Common Stock 2500000 0 D Warrants with Credit Facility of Oct 5, 2018 - T3 0.0386 2023-02-22 4 D 0 2500000 0 D 2019-03-29 2024-03-29 Common Stock 2500000 0 D Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. ("Emerald"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock. Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility. /s/ Stephen Hall, CFO of Emerald Health Sciences Inc. 2023-03-15